The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...
Things are, however, looking good for its latest launch, respiratory syncytial virus vaccine Arexvy, which GSK thinks can reach around $4 billion in annual sales. Zealand Pharma has suffered ...
Eliminating fake vaccine news with pharmacist, nurse, and physician review. According to the Pan American Health Organization (PAHO) chikungunya data dashboard, the Federative Republic of Brazil has ...